In the phase II Keynote-086 cohort B, the objective response rate of single-agent pembrolizumab in patients with PD-L1–positive metastatic triple-negative breast cancer was 21.4% (95% confidence interval, 13.9–31.4), with most of the responses being durable (16). Here, CD274 is linked to triple-negative breast carcinoma.